INTRODUCTION
Macrophages (MFs) straddle the innate and adaptive immune systems, playing important roles in homeostatic tissue maintenance and in the immunopathology of many diseases, including cancer, bacterial infections, trauma, and arthritis. [2] [3] [4] [5] To mediate these functions, MFs are highly plastic, responding to changes in the environment by taking on inflammatory (M1) or regenerative (M2) phenotypes. [6] [7] [8] Furthermore, specialized MFs perform critical functions in virtually all tissues, ranging from recycling heme in the kidney 9 to maintaining proper neuronal development in the brain. 10 Genetically engineering MFs can augment their homeostatic roles, phenotypic plasticity, and diverse tissue niches to resolve dysregulated tissue functions. These applications may utilize gene therapy to produce therapeutic proteins [11] [12] [13] [14] [15] or deliver poorly soluble drugs. [16] [17] [18] As MF biology is more extensively explicated, the broad range of behaviors that MFs possess provide an opportunity for engineering novel MF-based therapies.
The history of MF-based therapies began over 40 years ago, 19 but progress to date has been limited, due to the difficulty to generate the 10 7 -10 8 MFs required for human studies. 19 This barrier is partially because primary MFs do not usually proliferate in vitro, unlike T cells and mesenchymal stem cells (MSCs), which facilely proliferate in vitro. [20] [21] [22] The earliest clinical trials for MF-based cell therapies for cancer treatment occurred over 30 years ago, where large numbers of autologous MFs (10 8 -10 9 ) were collected from patient blood, conditioned with granulocyte macrophage colonystimulating factor (GMCSF) and interferon (IFN)g in vitro, and reinfused. 19, 23, 24 At best, two or three doses of MF could be collected and infused. While there were minimal side effects, the efficacy was modest and mixed (for a review of MF-based cell therapies, see Lee et al. 19 ). In more recent reports, tumor-derived MF-cell lines such as RAW264 or RAW309 have been used in animal studies. 11, 25 These lines are problematic for therapeutic development, due to their tumorigenicity. Studies that use bone-marrow-derived MFs lack a practical means to generate the MF numbers required for a therapy. 19 There have been a few reports of altering the expression of transcription factors to induce self-renewal in MFs and in myeloid progenitors, which can differentiate into MFs. These include MafB and c-Maf double-knockout (Maf-DKO) MFs 26 and Hoxb8-dependent myeloid progenitors (HDPs), which are held in a self-renewing state. 1, 27 Maf-DKO MFs and MFs derived from HDPs are functionally similar to endogenous MFs from other sources 26, 28 and are a good starting point for the development of MF-based therapeutics.
To perform further studies that required large numbers of MFs, we were interested in simplifying and accelerating the process of generating large numbers of MFs. The self-renewal capabilities of HDPs described by Wang and collaborators 1 were dependent upon a tamoxifen-dependent Hoxb8-ERT (estrogen receptor) and required culturing in 1 mM 4-hydroxytamoxifen (4-OHT). Removal of 4-OHT would stop Hoxb8 activity, and the HDP would differentiate into a MF. We asked whether a modified HDP with constitutively expressed Hoxb8 flanked by loxP sites and a 4-OHT-induced Cre recombinase could produce a self-renewing HDP that could undergo 4-OHT-inducible MF differentiation. HDPs also require the GMCSF to survive and proliferate. GMCSF signals through GMCSFR, and a single point mutation of GMCSFR (L452E) renders GMCSFR constitutively active and ablates the requirement for external GMCSF in myeloid cells. 29 We reasoned that the addition of constitutively active GMCSFR to HDPs would remove the need for the GMCSF to survive and proliferate.
To increase the rate of differentiation, we identified IRF8 as a transcription factor that is upregulated during MF differentiation. 30 By expressing 4-OHT-induced IRF8-ERT, we hypothesized that we could bypass the time required for IRF8 to be endogenously expressed and increase the differentiation rate of the HDP. By using a combination of lentivirus and retrovirus, we generated a modified HDP with constitutively active Hoxb8 and GMCSFR, as well as 4-OHT-inducible Cre and IRF8. To initiate differentiation, we cultured these modified HDP 4-OHT with ruxolitinib, a JAK1/2 inhibitor, to reduce GMCSFR activity and 4-OHT to activate Cre and IRF8. We demonstrate in this report that this new form of HDP, known as HDP-on, maintains the same growth and differentiation characteristics of the HDP, with cytokine-and 4-OHT-free self-renewal and 4-OHT-and ruxolitinib-inducible rapid differentiation into a MF.
Maf-DKO MFs are nontumorigenic when injected into an immunodeficient mouse. 26 However, it is unclear whether Maf-DKO MFs survive and engraft in this model. To our knowledge, there have been no reports of the in vivo survival of HDPs and HDP-derived MFs (HDP-MFs). We sought to quantitatively determine the survival potential of HDP-on cells and HDP-on-derived MFs (HDP-on-MFs) in immunodeficient NCG (lacking B, T, and natural killer [NK] cells) and immunocompetent BALB/c mice.
In this article, we describe two advances for the development of MF-based therapies: (1) a modified ex vivo method using Hoxb8, constitutively active GMCSFR, inducible Cre, and IRF8 (HDP-on) to facilely and rapidly generate large numbers of functional MF and (2) quantitatively validating the ability of clodronate-loaded liposome pretreatment to improve acute post-transplantation survival of HDP in immunocompetent BALB/c mice.
RESULTS

Hoxb8: A Method for Unlimited Myeloid Progenitors and MFs
Primary MFs are terminally differentiated cells and cannot be expanded in vitro. Recent reports described methods to circumvent this developmental block. One method, as described by Wang et al. 1 used tamoxifen-induced Hoxb8-ERT nuclear localization to hold a myeloid progenitor cell in a self-renewing state. This cell would differentiate into a MF when Hoxb8-ERT nuclear activity is reduced by the removal of 4-OHT from the media. 1 We modified this method by using a lentivirus to transduce primary lineage-negative (lin À ) bone marrow cells with a construct containing a constitutively expressed Hoxb8 flanked by loxP sites. Serial transduction with a Cre recombinase fused with ERT (Cre-ERT) endowed the cell with inducible Cre activity that could excise the Hoxb8 cassette with the addition of 4-OHT. This enables the differentiation of the progenitor cell toward a MF state that can be specified by the presence of GMCSF in the growth media ( Figure 1 ). The construct containing Cre-ERT also contained luciferase, a traceable marker, to allow the detection of live HDPs. Cells that die do not contribute to luciferase activity, as the enzyme has poor serum stability and has a very short circulatory half-life of under 20 min. 33 This reporter enables biodistribution studies by allowing for the total number of live cells to be determined from organ lysates. This cell, the HDP, formed the basis of our studies. HDPs require the GMCSF to proliferate and survive, which was provided by using a GMCSF supplement generated from the conditioned media of GMCSF-expressing L929 cells. Furthermore, HDPs can be cultured indefinitely in suspension culture to high densities (1-2 Â 10 6 /mL) and then differentiated into adherent MFs by adding 4-OHT to the media for 10 days. This model allows for the generation of the high number of HDPs and HDP-MFs required for the development of a MF-based therapy.
Constitutively Active GMCSFR HDPs Differentiate into MFs
To further enhance the performance of HDPs, two additional genetic modifications were made: a constitutively active GMCSFR and IRF8-ERT, forming the HDP-on ( Figure 1 ). Constitutively active GMCSFR results from a single point mutation (L452E) 29 and, in myeloid cells and MFs, results in survival and proliferation without the need for GMCSF. We hypothesize that this modification could potentially increase the overall in vivo survival, potential due to a limited pool of GMCSF in vivo. 34 Additionally, reducing the need for cytokine (either recombinant or from conditioned media) reduces the cost of materials to maintain these cells. HDP-on cells in media without GMCSF supplement proliferate as rapidly as HDPs with GMCSF supplement, with a doubling rate of $12 hr (Figure 2A ). This proliferation rate enables the rapid generation of a high number of cells for differentiation into MFs. To further enhance the ability to rapidly generate MFs, IRF8-ERT was also added to HDPs. IRF8 is a transcription factor that is upregulated during MF differentiation, 30 and constitutive expression of 4-OHT-inducible IRF8 results in a faster differentiation process by reducing the time for endogenous IRF8 to be expressed and migrate to the nucleus. In comparison to HDPs, which lack IRF8-ERT, the addition of IRF8-ERT reduces the time required for www.moleculartherapy.org differentiation from 10 to 6 days, further simplifying the amount of processing required to generate MFs. While HDPs require only 4-OHT to differentiate, HDP-on cells also require ruxolitinib, a Jak2 inhibitor that inhibits GMCSFR activity. Gene expression analysis of HDP-on cells differentiated for 6 days in 40 nM 4-OHT and 1 mM ruxolitinib by qPCR for MF-and HDP-specific genes 1, 27 reveals upregulation of the MF marker F4/80 (Emr1) and significant downregulation of HDP genes Elane, Prtn3, Ms4a3, and Plac8 (Figure 2B) . Flow-cytometric analysis of differentiating HDP-on cells over 6 days also demonstrates increased surface F4/80 expression ( Figure 2C ), a hallmark of MF differentiation. Ruxolitinib alone does not affect F4/80 expression, while 4-OHT alone increases F4/80 expression to a smaller degree. Combination treatment results in significantly more F4/80 expression by day 6, demonstrating the synergistic effects of ruxolitinib and 4-OHT on rapidly differentiating HDP-on cells into MFs. Based upon the gene expression and flow cytometry of differentiated HDP-on cells, we believe that HDP-on cells efficiently differentiate into MFs and could serve as a model for generating MFs for further studies.
HDP-on-MFs Retain M1/M2 Polarization Responses and Remain Highly Phagocytic
We determined whether HDP-on-MFs retained typical MF behaviors and phenotypes, using functional assays of phenotypic polarization and phagocytosis. One of the greatest potentials for MF-based therapies is to harness the plasticity of MFs by polarization toward inflammatory (M1) or regenerative (M2) phenotypes. The broad spectrum of phenotypes demonstrates the potential applications of MFs for a wide variety of conditions. It is important to note that the M1/M2 paradigm is not necessarily a binary distinction 6, 35 but, rather, describes a continuum of behaviors. However, there exist commonly accepted standards to describe M1-like and M2-like behaviors that can be elicited using specific polarization inducers. These methods were used to polarize and characterize HDP-onMFs. HDP-on-MFs treated with lipopolysaccharide (LPS), an M1 inducer, responded by upregulating known M1-associated genes IL12b, iNOS, and TNF ( Figure 3A) . Similarly, treatment with interleukin-4 (IL-4), an M2 inducer, upregulated the M2-associated genes Arg1, CD206, and CCL17 ( Figure 3A ). This was not observed in undifferentiated HDP-on cells treated with LPS or IL-4 ( Figure S1 ). Treatment of M1/M2-polarized HDP-on-MFs with the opposing polarization inducer also resulted in polarization to the opposing phenotype ( Figure S2 ). Based on these results, it is clear that HDP-on-MFs retain the plasticity that exists in conventionally derived MFs.
Another key function of MFs is their ability to phagocytose other cells or materials. MFs have also been proposed to act as drug carriers, 18, 36, 37 so demonstrating this ability is key to enabling this form of MF cell therapy. HDP-on-MFs were co-incubated with fluorescent DiD-labeled liposomes for 3 hr in serum-free media, and total lipid uptake was determined by measuring the total DiD fluorescence and comparing to a standard curve. RAW264, a MF cell line, was used as a positive control. Quantitative uptake studies demonstrated that HDP-on-MF and RAW264 cells exhibited a similar ability to phagocytose negatively charged liposomes ( Figure 3B ). Fluorescent imaging of HDP-MFs incubated with fluorescent HPTS liposomes and TagBFP-expressing E. coli also shows that HDP-on-MFs are highly phagocytic for both liposomes and E. coli ( Figure 3C ).
Undifferentiated HDP-on Cells and HDP-on-MFs Survive at Least 7 Days in Immunodeficient Mice
We next determined the survival potential of HDP-on and HDP-onMFs injected into the immunodeficient NCG strain of mice that lack B, T, and NK cells to determine whether HDP-MFs and HDP-onMFs survive in mice lacking an immune system. In some animals, live cells were detected in the peritoneal cavity and spleen ( Figure 4 ). In the peritoneal cavity, undifferentiated HDP-on cells demonstrated significantly greater survival than HDPs (151% ± 4% versus 107% ± 4% of the injected cells, or 7.55 Â 10 6 cells versus 5.35 Â 10 6 cells; p < 0.01). However, this trend was reversed in the spleen, where there were significantly fewer HDP-on cells than HDPs (11% versus 2% of the injected cells, or 5 Â 10 5 cells versus 1 Â 10 5 cells; p < 0.01).
MFs derived from either HDPs or HDP-on cells had significantly reduced survival in the peritoneal cavity (4.4% ± 0.3%, 2.2 Â 10 5 cells;
and 19.4% ± 3.3%, 9.7 Â 10 5 cells, respectively) when compared to the respective parental cell. Neither MF type was detected in the spleen. Other tissues were analyzed, including the liver, heart, bone marrow, lungs, brain, kidney, and blood, but the combined percentages of injected cells detected across these tissues was below 1.5% of injected cells in all conditions tested ( Figure S3 ).
Furthermore, there was a differential in the number of cells recovered between the peritoneal cavity and spleen, with HDP-on cells having a greater number of cells in the peritoneal cavity than HDPs. The opposite was true in the spleen ( Figure 4 ). Overall, these experiments indicate that both HDPs and HDP-MFs with or without HDP-on modifications can survive at least 7 days in immunodeficient animals.
Clodronate Pretreatment Improves Survival of HDP-on Cells in Immunocompetent Mice
Due to the significantly higher survival of HDPs and HDP-on cells when compared to the differentiated MFs in immunodeficient NCG mice, we focused on determining the survival of undifferentiated HDPs and HDP-on cells in healthy immunocompetent BALB/c mice ( Figure 5 ). HDPs were not detected in any tissues at 1 or 7 days post-transplantation. HDP-on cells had significantly higher survival in the peritoneal cavity 1 day post-transplantation, compared to HDPs (107% ± 21% or 5.35 Â 10 6 cells; p < 0.001). However, survival of HDP-on cells in other tissues was limited: at 1 day posttransplantation, <1% was detected in the spleen or liver; and at 7 days post-transplantation, <0.5% was detected in the liver, and no cells were detected in the peritoneal cavity or spleen. For other tissues, including, brain, lung, heart, bone marrow, liver, spleen, kidneys, and blood, the total combined percentage of injected cells detected for either HDPs or HDP-on cells was below 1% of the injected cells (Figures S4 and S5).
We sought to improve the survival of either HDPs or HDP-on cells and hypothesized that the removal of endogenous MFs may improve survival, since improved survival of other cell types has been reported when animals are pretreated with MF-killing liposomal clodronate.
Endogenous MFs are found in tissue niches that transplanted HDPs might be able to occupy. Successful transplantation of MFs has been reported in Csf2rb-KO mice, which have impaired MF activity and reduced numbers of MFs. 34, 39 Additionally, F4/80 + cells phagocytose stem-cell-derived hematopoietic progenitor cells 38 and could be involved in removing HDPs. Hence, the removal of endogenous MFs may be beneficial for HDPs by creating a niche and interfering with active removal by endogenous MFs. Endogenous MFs can be transiently removed from the peritoneal cavity, liver, spleen, and blood with liposomal clodronate. 40, 42, 43 We accomplished this by injecting 100 mL liposomal clodronate (5 mg/mL) intraperitoneally (i.p.) 1 day and 4 days prior to the injection of cells.
At 1 day post-transplantation, liposomal clodronate pretreatment only increased survival in the peritoneal cavity for HDPs, and no benefit was detected in other tissues. Compared to HDP survival in untreated mice, liposomal clodronate pretreatment significantly improved the survival of HDPs in the peritoneal cavity (95% ± 7.1% or 4.75 Â 10 6 cells versus undetectable; p < 0.001). This improvement was sustained at 7 days post-transplantation, with 85% ± 15% (4.25 Â 10 6 cells versus undetectable; p < 0.001) of the injected cells detected in the peritoneal cavity. HDP-on cells did not experience any significant improvement in the peritoneal cavity with liposomal clodronate pretreatment at 1 day post-transplantation when compared to untreated animals (90% ± 10% or 4.5 Â 10 6 cells versus 107% ± 20% or 5.35 Â 10 6 cells). However, HDP-on cells experienced significant enhancement in survival at 7 days post-transplantation in the peritoneal cavity when compared to animals that did not undergo liposomal clodronate pretreatment (60% ± 17% or 3 Â 10 6 cells versus undetectable; p < 0.05).
No improvements were seen in tissues other than the peritoneal cavity at 1 day post-transplantation. At 7 days post-transplantation, improvement in cell numbers was seen in the spleen and liver for both HDPs and HDP-on cells. In the spleen, HDPs increased from undetectable to 21.2% ± 2.7% (1.06 Â 10 6 cells; p < 0.001), and HDP-on cells increased from undetectable to 3.4% ± 0.9% (1.5 Â 10 5 cells; not significant). The enhancement was more modest in the liver, with HDPs increasing from undetectable to 1.35% ± 0.1% (6.75 Â 10 4 cells; p < 0.001) and HDP-on cells increasing from 0.22% ± 0.08% (1.1 Â 10 4 cells) to 0.86% ± 0.18% (4.3 Â 10 4 cells; p < 0.01). In other tissues tested, there was no measurable benefit with respect to the cell number found in the tissue ( Figures  S4 and S5) . To summarize, in immunocompetent BALB/c mice, the HDP-on modifications significantly improved the number of HDPs that survived in the peritoneal cavity 1 day post-transplantation via the intraperitoneal route of administration. This benefit is not maintained, because no cells were detected at 7 days. Liposomal clodronate pretreatment to remove endogenous MFs increased the peritoneal cavity survival at 1 day post-transplantation of HDPs to levels similar to those of HDP-on cells. Liposomal clodronate pretreatment improved the survival of HDPs and HDP-on cells at 7 days post-transplantation in the peritoneal cavity, spleen, and liver. MFs differentiated from HDPs and HDP-on cells did not show increased survival in any tissue in the liposomal-clodronate-treated animals ( Figure S6 ).
Liposomal Clodronate Pretreatment Does Not Enhance Posttransplantation Cell Survival in Immunocompetent Mice beyond 7 Days
We determined whether liposomal clodronate pretreatment enabled the long-term survival of HDP-on cells beyond 7 days. HDP-on cells were injected i.p. into NCG mice that were not treated with liposomal clodronate and in liposomal-clodronate-pretreated BALB/c mice. Liposomal clodronate was not used in NCG mice due to unacceptably high mortality, even at reduced doses of 15 mg/kg (data not shown). To determine the kinetics of in vivo survival post-transplantation for liposomal-clodronate-pretreated BALB/c mice, mice were euthanized at multiple time points and their data were combined with data from the previous section to determine the biodistribution at 1, 3, 7, and 14 days post-transplantation. Similarly, biodistribution was also performed in NCG mice at 7 and 14 days post-transplantation.
The long-term survival of HDP-on cells was limited in liposomalclodronate-treated BALB/c mice ( Figure 6 ). In these mice, the number of live cells detected in the peritoneal cavity decreased steadily 1 day post-transplantation and were undetectable at 14 days. In the liver, spleen, kidney, and bone marrow, the number of HDPon cells increased from 1 day to 7 days post-transplantation. The total percentage of injected cells detected in these tissues at 7 days ranged from a low of 0.4% in the kidney to a high of 4% in the spleen. However, similar to the peritoneal cavity, 14 days post-transplantation, no cells were detected in these tissues. At no point were HDPon cells detected in the brain, heart, lung, or blood in BALB/c mice ( Figure S7 ).
In NCG mice, the number of live HDP-on cells increased across all tissues between 7 days and 14 days post-transplantation. In the peritoneal cavity, the total percentage of injected cells detected increased from 151% ± 4% (7.55 Â 10 6 cells) at 7 days to 718% ± 208% (35.9 Â 10 6 cells) at 14 days post-transplantation, representing a 4.75-fold enhancement. The relative increase between 7 and 14 days was also high in the other organs, with 75-, 4-, 26-, and 29-fold enhancement, in the liver, spleen, kidney, and bone marrow, respectively. HDP-on cells were detected at 14 days in other tissues (brain, blood, and lungs), which did not show live cells in any other conditions we have tested ( Figure S8) . Furthermore, at 14 days, NCG mice displayed significant morbidity and mortality and were euthanized in accordance with UCSF IACUC protocols.
DISCUSSION
In this study, we demonstrated that (1) HDPs modified with a constructively active GMCSFR and IRF8-ERT (HDP-on cells) can self-renew without cytokine and rapidly differentiate into MFs; (2) HDP-on-MFs retain MF-like behaviors, including phagocytosis and M1/M2 polarization; (3) HDP-on cells and HDP-on-MFs persist in immunodeficient NCG mice for at least 7 days, using a quantitative luciferase-based assay; and (4) liposomal clodronate pretreatment enhances the survival of transplanted HDP-on cells in healthy BALB/c mice for at least 7 days.
We modified a method developed by Wang et al. 1, 27 to hold myeloid progenitors in a self-renewal state by inserting a constitutively ex- Previous reports using MFs for cell-based therapies 19 have used bone-marrow-derived MFs 34, 39 or immortalized RAW264 cell lines, 11, 25 which are either limited in number or highly transformed. Using HDPs, we were able to easily genetically engineer HDP cells using retrovirus to tailor the cell for various applications, generate large numbers of HDP cells, and differentiate these cells into functional MFs. The ability to generate large numbers of cells is especially important. Other cell-based therapies, including T cell and stem cell therapies, rely on self-renewing cell types to generate therapeutic doses of the cell for animal and clinical studies. [20] [21] [22] Primary MFs do not normally proliferate in vitro, so the methods described here reduce barriers for the evaluation of MF cell-based therapies. Having these cells enabled us to study the biodistribution of HDPs and MFs in immunocompromised NCG and healthy BALB/c mice.
There has been relative paucity in quantitative approaches to determine the biodistribution of MF-based therapies. 19 Most studies have relied on qualitative measures such as a biological functional response, histology, or flow cytometry. While these methods may determine the presence of the transplanted cell, a quantitative approach is needed to measure biodistribution, dose response, and cell survival to better assess and develop cell-based therapies. We used a luciferase-based system, as it provided a quantitative method to count only live cells due to poor serum stability of luciferase when a cell dies.
Endogenous MFs may serve as barriers to the post-transplantation survival of HDP-on cells and HDP-on MFs. This may be due to the highly phagocytic nature of MFs, or the lack of a tissue niche for transplanted cells to survive. Phagocytic endogenous MFs are responsible for the low post-transplantation survival of embryonic-stem-cell-derived hematopoietic progenitors in the highly immunodeficient NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mouse model. 38 Long-term post-transplantation survival of wild-type bone-marrow-derived MFs have been observed in a Csf2rb KO mouse, which possesses small numbers of dysfunctional MFs. 34, 39 In this model, the lack of functional MFs may have allowed the functional MFs to engraft and survive. Much like how immunoablation by chemoablation or sublethal radiation is used to prepare hosts for the transplantation of T cells or hematopoietic stem cells, 21 the removal of endogenous MFs may generate tissue niches for transplanted HDP-on cells and HDP-on-MFs to enable long-term survival. Administration of liposomal clodronate has been shown to temporarily eliminate endogenous MFs, 40 and we observed that pretreating mice with liposomal clodronate increases the post-transplantation survival of HDP-on cells but not HDP-on-MFs. The robust survival in NCG mice indicated that HDPs can survive with only endogenous cytokines in vivo. Detecting more than 100% of the injected cells is very significant, as it also indicates that cells are proliferating in vivo. The substantial reduction in surviving MFs in both NCG and BALB/c mice may be indicative of the transplantation process being more deleterious on MFs or that the peritoneal cavity may lack the survival factors required to support the survival of the 5 Â 10 6 MFs that were transplanted. Additionally, biodistribution studies conducted by transplanting cells via the intravenous route did not result in any cells detected beyond 1 day in any organ (data not shown).
Administration of liposomal clodronate via the peritoneal cavity temporarily removes MFs from the peritoneal cavity, spleen, liver, and blood. 40 Thus, removal of endogenous MFs may be responsible for the improved HDP survival in liposomal-clodronate-treated BALB/c mice in the peritoneal cavity (60%-85% of total injected cells at 7 days), liver (0.9%-1.3%), spleen (3%-21%), kidney (<1%), and bone marrow (<1%). In support of this observation, MFs are primarily responsible for removing embryonic-stem-cell-derived hematopoietic progenitors. 38 The enhanced HDP survival after liposomal clodronate treatment is probably due to the removal of endogenous MFs. The endogenous MFs may phagocytose transplanted HDPs or occupy tissue niches required by HDPs for longer term survival. 8 In BALB/c mice pretreated with liposomal clodronate, the number of HDP-on cells steadily increased in the spleen, liver, kidneys, and bone marrow site over 7 days, indicating migration from the peritoneal cavity to other tissues. However, no HDP-on cells were detected at 14 days in any tissues. We believe that the loss of HDP-on cells between 7 and 14 days is possibly related to the re-establishment of endogenous tissue MF populations. After liposomal clodronate treatment, MFs repopulate in the mouse spleen and rat liver within 7-14 days. 44, 45 The returning endogenous MFs may phagocytose the transplanted HDP-on cells and/or reoccupy the niche. To improve long-term survival of HDP-on cells, repeated clodronate treatment may be required post-transplantation. Liposomal mice. 34, 39 These mice have a significantly reduced number of endogenous lung MFs, which could result in niches for the transplanted MFs to occupy. Furthermore, Csf2rb encodes for the GMCSF receptor, which provides both survival and proliferation signals to MFs in the presence of GMCSF. Thus, the wild-type MFs had a survival and proliferative advantage over the endogenous Csf2rb À/À MFs and, over time, were able to outcompete the endogenous MFs for the remaining niches. The addition of HDP-on modifications to HDPs possibly provides a proliferative/survival advantage that did not appear to mimic the effect observed in these studies. However, our studies used a different route of administration in healthy mice. Long-term survival of transplanted MFs may be more successful in appropriate disease models with impaired MFs.
Based upon the survival of HDPs in NCG mice beyond 7 days, it is clear that the immunodeficiencies of NCG mice have an impact on the survival of HDPs. Immunodeficient NCG mice possess MFs, yet HDP-on cells survive beyond 7 days. This would imply that B, T, or NK cell activity may also be responsible for the loss of transplanted HDPs in BALB/c mice. Syngeneic cells were injected into BALB/c mice, but the HDPs were extensively modified to express foreign proteins, including fluorescent proteins, antibiotic resistance markers, and luciferase. These types of foreign proteins can be immunogenic and lead to the rejection of transplanted cells. [47] [48] [49] Rejection of GFP-expressing cells has been strongly associated with T cells, 47 and NK cells target stem-cell-derived hematopoietic progenitors. 50 Swijnenburg and colleagues performed studies with human embryonic stem cell xenografts into mice and dissected the immune response to identify CD4 + T cells and the adaptive immunity response as responsible for the loss of transplanted cells. 51, 52 Using histology and flow cytometry on tissue digests, they identified significant immune cell (T, B, MF, and neutrophil) infiltration in the injection site. 52 Furthermore, when immunocompetent mice received a second injection of stem cells, no cells were detected at 3 days post-injection. 51 Similarly, in BALB/c mice that received an additional round of liposomal clodronate and a second HDP-on injection (liposomal clodronate on day À4 and day À1, HDP-on injection on day 0, second round of liposomal clodronate on days 7 and 11, and second HDP-on injection on day 12; Figure S9 ), no cells were detected in any tissue 3 days after the second dose. Additionally, in mice that received the xenograft, splenocytes secreted more IL-4 than IFNg, which, respectively, corresponded to Th2 (humoral immunity) and Th1 (cellular immunity) responses. Immunoglobulin (Ig)M levels were also significantly higher after transplantation. Swijnenburg and colleagues performed xenograft survival studies in Nude, CD4 À , and CD8 À mice to determine CD4 + T cells as mediators for removing the xenograft. 51 Finally, they identified that a pretreatment strategy of a combination of tacrolimus (a calceinurin inhibitor) and rapamycin enabled the xenograft to survive for at least 28 days. 51 We believe that the combination of humoral and cellular immune responses they observed may also be applicable to HDP-on cells in syngeneic animals. Further experiments, using an array of immunodeficient mice or B/T/NK-cell-depletion strategies, are required to isolate the cell type(s) responsible for the rejection of HDP-on cells.
A similar drug treatment approach, targeting T cell activity, may also enhance the survival of HDPs. 53 Other methods, such as blockade of co-stimulatory molecules (anti-LFA1, anti-CD40L, or anti-CD80) or genetically engineering cells to reduce major histocompatibility complex (MHC) class I or increase immunosuppressive cytokine production, may also be explored to increase survival. 54 To summarize, we describe a modified HDP system to generate large numbers of fully functional MFs and use these cells to perform quantitative biodistribution studies. We found that liposomal clodronate pretreatment increases the in vivo survival of transplanted HDP-on cells from 1 to 7 days. Experiments in NCG mice demonstrated the survival and expansion of HDP-on cells to at least 14 days, demonstrating the role of B, T, and/or NK cells in preventing longer term survival. Our proposed model for this behavior is that HDP-on cells are removed by two overlapping mechanisms ( Figure 7 ). The first is mediated by endogenous MFs, which act within 7 days to remove transplanted cells. The second is mediated by B, T, and/or NK cells and removes transplanted cells beyond 7 days. Therefore, while liposomal clodronate and genetic modifications may enhance the acute survival of HDPs, further efforts must be made to reduce the impact of the humoral and cell-mediated immune responses to increase the long-term survival of transplanted HDPs.
MATERIALS AND METHODS
Cell Culture
Reagents were acquired from the University of California, San , using tissue-culture-treated flasks from Grenier Bio-One (product #658170) in a humidified incubator maintained at 37 C and 5% CO 2 . Cells expressing the constitutively active GMCSFR were cultured without the GMCSF supplement. Cell counts were determined using a hemocytometer, and live cells were enumerated using trypan blue staining.
HDPs and HDP-on cells were differentiated into MFs using different protocols. MFs derived from HDPs were differentiated by culturing cells in 200 nM 4-OHT (Enzo Life Sciences) for 10 days. Differentiation was started with a cell density of 2-4 Â 10 5 cells per milliliter, and the media were changed every 2 days for the first 6 days. Thereafter, no media changes were performed until MF were collected on day 10. MF differentiated from HDP-on cells were differentiated using 40 nM 4-OHT and 1 mM ruxolitinib (Selleckchem) for 6 days. Differentiation was started with a cell density of 2-4 Â 10 5 cells per milliliter, and the media were changed only on day 3.
Plasmid Construction
Plasmids for lentivirus and retrovirus production were cloned using standard techniques, including restriction cloning and Gibson assembly, depending on the applicability of each technique to the desired product. For the production of plasmids containing Hoxb8 (NCBI Gene ID: 15416), GMCSFR (NCBI Gene ID: 12983), and IRF8 (NCBI Gene ID: 15900), murine cDNAs were acquired from GE Dharmacon and cloned into pLVX or pMSCV vectors for lentivirus or retrovirus production, respectively, as described in the following section. Expression constructs also encoded antibiotic selection markers: blasticidin (bsd), puromycin (puro), zeocin (zeo), and neomycin (neo). To engineer the constitutive activity of GMCSFR, a QuikChange Lightning kit (Agilent Technologies) was used to modify the leucine in position 452 to glutamic acid (L452E), as adapted from Perugini et al. 29 Vectors for plasmid construction were obtained from Addgene or commercially available from Clontech Laboratories. Constructs were sequence verified before use. were cultured overnight in 100 ng/mL stem cell factor (SCF) (#250-03), 10 ng/mL IL-3 (#213-13), and 20 ng/mL IL-6 (#216-16) (all cytokines were murine and obtained from PeproTech) before they were transduced by lentivirus encoding the Hoxb8 construct. Following transduction with the Hoxb8 lentivirus, the cells were cultured in 30 ng/mL GMCSF (Peprotech, 315-03).
Lentivirus and Retrovirus Production
A second-generation lentivirus was used, requiring three plasmids: pCMV-dR8.91 (Delta 8.9) (containing gag, pol, and rev genes; Addgene #12263), VSV-G (envelope; Addgene #8454), and expression construct (pLVX-insert; Clontech #632187). For murine stem cell retrovirus, two plasmids are required: the packaging vector (pCL-Eco; Addgene #12371) and the expression construct (pMSCV; Clontech #634401). To produce either retroviral or lentiviral vectors, HEK293T cells were transfected using Lipofectamine 2000 (Life Technologies) with the required plasmids, and the media were collected and replaced every day for 3 days (see Supplemental Materials and Methods). The media containing the virus vector were concentrated by mixing 1:3 (v/v) with Lenti-X or Retro-X concentrator (Clontech) overnight and centrifugation at 3,000 rpm for 30 min in a 50-mL conical tube. The concentrated virus vector was resuspended in 200 mL RPMI and was used without further purification for viral vector transduction.
Lentiviral and Retroviral Transduction
Cells were transduced with retrovirus or lentivirus vectors using the Spinfection method, as described in the Supplemental Materials and Methods. 31 Briefly, 2 Â 10 4 cells were added to a RetroNectin (Clontech #T100B)-treated 48-well plate along with 50 mL retrovirus or lentivirus vector. The plate was centrifuged for 90 min at 1,500 Â g and 30 C. The culture was then allowed to recover overnight in a humidified 5% CO 2 32 C incubator. The following day, the culture was returned to a humidified 5% CO 2 37 C incubator. After 3-5 days, the culture was expanded and tested for integration of the desired modifications. For antibiotic selection, 6 mg/mL blasticidin, 0.2 mg/mL puromycin, 30 mg/mL zeocin, or 1 mg/mL neomycin (Life Technologies) was added to the media.
MF M1/M2 Polarization
MFs were prepared as described previously. To polarize MFs, the media were changed for the appropriate polarization media: 10 ng/mL LPS (Sigma), or 100 ng/mL IL-4 (Peprotech) for M1 or M2, respectively. Following an overnight treatment, MFs were washed with D-PBS, and RNA was collected using the RNeasy Mini Kit (QIAGEN) following manufacturer protocols. The expression of M1/M2 genes was then measured by qRT-PCR.
Real-Time qPCR
RNA was collected from cell samples as previously described. cDNA for real-time qPCR was produced using the SuperScript VILO cDNA Synthesis Kit (ThermoFisher). Real-time qPCR was performed using SsoFast EvaGreen Supermix (BioRad) following manufacturer protocols, using a BioRad CFX96 thermal cycler. Each readout was normalized against an internal mouse beta-actin expression value and then compared to matched genes in other samples to determine fold change. For each sample and each gene, three replicates were performed, and the fold enhancement was averaged to yield a single value. To generate multiple values for statistical analysis, multiple experimental samples, as indicated in the relevant figure, were subjected to the described method. For primer sequences, please refer to the Supplemental Materials and Methods.
Flow Cytometry
Flow cytometry was conducted at the UCSF Flow Cytometry core on a BD Fortessa instrument (see Supplemental Materials and Methods). The isotype antibody control used was APC-labeled Rat IgG2a, k (BioLegend, Clone RTK2758). Fc-receptor blocking was performed using rat anti-mouse CD16/CD32 (BD PharMingen, Clone 2.4G2). Cells were labeled with allophycocyanin (APC)-labeled rat anti-F4/80 (BioLegend, Clone BM8, Rat IgG2a, k) according to the manufacturer's instructions, and the data were analyzed using FlowJo software. Before analysis, dead cells and doublets were removed using forward scatter (FSC) and side scatter (SSC) gating.
MF Phagocytosis
Fluorescent liposomes were prepared with a 3:1:2 mole ratio of HSPC:DSPG:cholesterol (HSPC: L-a-phosphatidylcholine, hydrogenated (Soy); DSPG: 1,2-distearoyl-sn-glycero-3-phospho-(1'-racglycerol) [Avanti Polar Lipids]) with 1% 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS) (Sigma). The mixture of lipids in chloroform were placed in a round-bottom flask, and the chloroform was removed using a rotary evaporator. The resulting lipid film was dried under high vacuum overnight at room temperature. The film was reconstituted with HBS (140 mM NaCl, 10 mM HEPES) and sonicated under argon at room temperature for 40 min to form liposomes. The liposomes were then dialyzed for 24 hr in 2 L HBS in a 10,000-molecular-weight (MW) dialysis cassette (ThermoScientific) to remove unencapsulated HPTS and sterile filtered through a 0.45 mm filter (Millipore). For quantitative studies, liposomes were prepared in a similar fashion, using a 1:3:2 mole ratio of DSPG/DSPC/cholesterol (DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine) with 0.01% DiD (Biotium). Lipid films were prepared as described and sonicated with D-PBS under argon at 45 C for 20 min. DiD-labeled liposomes were extruded through a 100-nm polycarbonate membrane before sterile filtering through a 0.45 mm filter. The size and charge of the liposomes were determined using a Zetasizer (HPTS: diameter, 76 nm; PDI, 0.76; charge, À57 mV; DiD: diameter, 116 nm; PDI, 0.216; charge, À27.3 mV). Fluorescent bacteria were generated by transforming a BL21 E. coli strain with a pGEX-TagBFP plasmid.
Uptake experiments were performed on MFs differentiated from HDPs treated with 200 nM 4-OHT for 10 days or HDP-on cells treated with 40 nM 4-OHT and 1 mM ruxolitinib for 6 days. MFs were removed from T-75 tissue culture plates using 5 mL HyQTase (GE Healthcare) for 10 min, and 1 Â 10 5 MFs were plated overnight in 1 mL media in a 12-well plate prior to incubation with liposomes or bacteria. For fluorescent imaging, MFs were incubated with 1 mL 500 mM HPTS-liposome solution or 1 mL 10% live TagBFP-E. coli culture (optical density 600 [OD 600 ] = 0.5) in serum-free media for 3 hr or 30 min, respectively, in a humidified 5% CO 2 37 C incubator. Following the incubations, wells were rinsed three times with 1 mL D-PBS. Cultures treated with bacteria were imaged without any further treatment, while liposome-treated cultures were stained with DAPI prior to imaging on a fluorescent microscope. For quantitative liposomal uptake studies, 1 Â 10 5 MFs were plated overnight in 1 mL media in a 12-well plate prior to incubation with liposomes. The next day, MFs were incubated with DiD liposomes at varying concentrations in serum-free media for 6 hr in a humidified 5% CO 2 37 C incubator. The MF cell line, RAW264, was used as a comparative phagocytosis positive control cell line. The wells were washed with D-PBS three times, and then the cells were lysed with 1 mL radio immunoprecipitation assay (RIPA) buffer (150 mM NaCl [Sigma], 1% Triton-100 [Sigma], 10% glycerol [molecular grade; Roche], and 50 mM Tris [Fisher Scientific]). Total fluorescence was measured using a spectrofluorometer (Fluorlog; Horiba) (excitation, 644; emission, 665). The amount of liposomes taken up by the cells was determined from a standard curve of DiD liposomes in RIPA buffer. To normalize the fluorescence signal to the number of MFs in the well, total protein was measured using a BCA Protein Assay Kit (ThermoFisher).
Animals
All mice used in this study were purchased from Charles River Laboratories (Wilmington, MA) and maintained under pathogenfree conditions at the University of California, San Francisco (UCSF). All mouse procedures were approved by the UCSF Institutional Animal Care and Use Committee (IACUC). Two mouse strains were used in this study: BALB/c (strain #028) and NCG (NODPrkdc em26Cd52 Il2rg em26Cd22 /NjuCrl; strain #572). Due to their immunodeficient status, NCG mice were housed in ultraclean barrier facilities.
Cell Transplantation
Adherent MFs were removed from T-75 tissue culture flasks by treatment with 5 mL HyQTase (GE Healthcare) for 10 min and gentle tapping of the flask. After removal from the flask, the cells were treated identically to suspension cells. Suspension HDP cells were washed twice with plain RPMI buffer and counted, and the required dose was resuspended in 500 mL for intraperitoneal injection. For each biodistribution experiment, the luciferase activity per cell was determined to calculate the total luciferase units injected into the mouse.
Mice that were treated with liposomal clodronate (ClodLip BV) were dosed twice (4 days and 1 day prior to cell injection) with 100 mL liposomal clodronate (5 mg/mL) i.p. After the injection, the mouse was placed in a cage and observed for 10 min to ensure no adverse effects. No adverse effects were ever observed during this observation period. However, as reported by other groups, there was a 20%-25% mortality within 5 days of liposomal clodronate treatment. 32 All animals were female and 8-10 weeks old at the time of injection.
Biodistribution
Animals were euthanized by an intraperitoneal injection of sodium pentobarbital (200 mg/kg) and cervical dislocation, as approved by UCSF IACUC. Organs were collected, weighed, and placed on ice. Each organ was lysed with RIPA buffer ($200 mg tissue per milliliter of RIPA buffer) using a glass dounce grinder with a tight-fitting pestle, and a lysate was formed by using the pestle until no tissue was visible. The organ lysates were centrifuged at 3,000 rpm for 5 min, and the supernatant was used for further analysis. Blood samples ($50-200 mL) were collected into a tube containing 10 mL of 1 mg/mL heparin in D-PBS (Alfa Aeser) and were not processed further. Flushes of the peritoneal cavity were collected by injecting 5 mL of plain RPMI medium into the peritoneal cavity of a euthanized mouse. The mouse abdomen was massaged slightly to ensure proper mixing in the peritoneal cavity before a cut was made into the abdomen to drain the fluid with suspended cells into a collection dish. This suspension was transferred to a 15-mL tube and stored on ice until ready for measurement. Immediately prior to the luciferase activity measurement of samples from the peritoneal cavity, the cell suspension was mixed thoroughly by inverting the tube several times.
Luciferase activity was determined using SteadyGLO (Promega), as per manufacturer protocols. Clarified organ lysate (100 mL) was mixed with 100 mL SteadyGLO in a glass tube. Total luminescence was measured using a luminometer (MGM Instruments) over a 10-s period. The luciferase activity from the measured sample was multiplied with an appropriate correction factor to determine the total luciferase activity in each organ. The percentage of injected cells in each organ was calculated by dividing the total luciferase activity in each organ by the total luciferase activity of the injected cells. In control experiments, the presence of organ lysate did not reduce the luciferase activity of a known number of cells by more than 10%, compared to cells in RIPA alone (data not shown).
Statistics
Statistics analysis was performed using GraphPad Prism 5. To determine the significance between datasets, one-way ANOVA was performed, followed by a Bonferroni post-test. For comparison of pharmacokinetic data, a one-sided t test was used to compare within the same time point. Significance was reported as follows: *p < 0.05, **p < 0.01, or ***p < 0.001. Error bars represent SE.
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